LABFF OTC
Laboratorios Farmaceuticos Rovi, S.A.
1W: +0.0%
1M: +0.0%
3M: -25.0%
YTD: -25.9%
1Y: -25.9%
3Y: +34.9%
5Y: +4.7%
$67.17
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$743M
-2.7% ▼
5Y CAGR: +12.1%
Gross Profit
$451M
-3.5% ▼
5Y CAGR: +13.7%
Operating Income
$173M
-3.6% ▼
5Y CAGR: +18.3%
Net Income
$140M
+2.6% ▲
5Y CAGR: +18.1%
EPS (Diluted)
$2.75
+3.0% ▲
5Y CAGR: +20.1%
EBITDA
$203M
+1.9% ▲
5Y CAGR: +17.8%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $649M | $818M | $830M | $764M | $743M |
| YoY Growth | +54.5% | +26.1% | +1.4% | -7.9% | -2.7% |
| Cost of Revenue | $269M | $305M | $346M | $296M | $292M |
| Gross Profit | $380M | $512M | $483M | $468M | $451M |
| Gross Margin | 58.6% | 62.7% | 58.3% | 61.2% | 60.7% |
| R&D Expenses | $28M | $24M | $25M | $26M | $38M |
| SG&A Expenses | $103M | $130M | $147M | $158M | $233M |
| Operating Expenses | $198M | $257M | $263M | $288M | $278M |
| Operating Income | $181M | $256M | $220M | $180M | $173M |
| Operating Margin | 28.0% | 31.3% | 26.6% | 23.5% | 23.3% |
| Interest Expense | $907K | $844K | $948K | $2M | $3M |
| Income Before Tax | $183M | $258M | $220M | $178M | $183M |
| Tax Expense | $30M | $58M | $50M | $41M | $43M |
| Net Income | $153M | $200M | $170M | $137M | $140M |
| Net Margin | 23.6% | 24.4% | 20.5% | 17.9% | 18.9% |
| EPS (Diluted) | $2.76 | $3.73 | $3.20 | $2.67 | $2.75 |
| EBITDA | $197M | $271M | $238M | $200M | $203M |
| Shares Outstanding | 55M | 53M | 53M | 51M | 51M |